ALK immunohistochemistry for ALK gene rearrangement screening in non-small cell lung cancer: A systematic review and meta-analysis

International Journal of Biological Markers

Volumn 31, Issue 4, 2017, Pages e413-e421

  Pyo, Jung Soo ^a,c   Kang, Guhyun ^b   Sohn, Jin Hee ^a  

^a School of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Eulji University   (South Korea)

Author keywords

ALK; Diagnostic test accuracy review; Fluorescence in situ hybridization; Immunohistochemistry; Metaanalysis; Non small cell lung carcinoma

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; PROTEIN TYROSINE KINASE;

ALK GENE; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; META ANALYSIS; NON SMALL CELL LUNG CANCER; RECEIVER OPERATING CHARACTERISTIC; SYSTEMATIC REVIEW; EARLY CANCER DIAGNOSIS; ENZYMOLOGY; GENETICS; LUNG TUMOR; PATHOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; EARLY DETECTION OF CANCER; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 85008191199     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/jbm.5000218     Document Type: Article

References (56)

1. Lindeman NI, Cagle PT, Beasley MB, et al; College of American Pathologists, International Association for the Study of Lung Cancer and Association for Molecular Pathology. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors:guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn.2013;15(4): 415-453.
2. Travis WD, Brambilla E, Burke AP, et al. WHO classification of tumours of the lung, pleura, thymus and heart. 4th ed. Lyon, France: International Agency for Research on Cancer, 2015.
3. Kim H, Shim HS, Kim L, et al; Korean Cardiopulmonary Pathology Study Group. Guideline recommendations for testing of ALK gene rearrangement in lung cancer: a proposal of the Korean Cardiopulmonary Pathology Study Group. Korean J Pathol.2014;48(1): 1-9.
4. Pyo JS, Sohn JH, Kim WH. Concordance rate between HER2 immunohistochemistry and in situ hybridization in gastric carcinoma: systematic review and meta-analysis. Int J Biol Markers. 2016;31(1): e1-e10.
5. Takeuchi K, Togashi Y, Kamihara Y, et al. Prospective and clinical validation of ALK immunohistochemistry:results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study). Ann Oncol. 2016;27(1): 185-192.
6. Shen Q, Wang X, Yu B, et al. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC). Lung Cancer. 2015;90(3): 492-498.
7. Cruz-Rico G, Avilés-Salas A, Segura-González M, et al. Diagnosis of EML4-ALK translocation with FISH, immunohistochemistry, and real-time polymerase chain reaction in patients with nonsmall cell lung cancer. Am J Clin Oncol. 2015; Aug 11.
8. Savic S, Diebold J, Zimmermann AK, et al. Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended. Lung Cancer. 2015;89(2): 104-109.
9. Lantuejoul S, Rouquette I, Blons H, et al. French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas. Eur Respir J. 2015;46(1): 207-218.
10. Gruber K, Kohlhäufl M, Friedel G, Ott G, Kalla C. A novel, highly sensitive ALK antibody 1A4 facilitates effective screening for ALK rearrangements in lung adenocarcinomas by standard immunohistochemistry. J Thorac Oncol. 2015;10(4): 713-716.
11. Rogers TM, Russell PA, Wright G, et al. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer. J Thorac Oncol. 2015;10(4): 611-618.
12. Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L, et al. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist. 2015;20(3): 316-322.
13. von Laffert M, Warth A, Penzel R, et al. Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria. J Thorac Oncol. 2014;9(11): 1685-1692.
14. Ilie MI, Bence C, Hofman V, et al. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK ‘borderline’-positive rearrangements or a high copy number:a potential major issue for anti-ALK therapeutic strategies. Ann Oncol. 2015;26(1): 238-244.
15. Sullivan HC, Fisher KE, Hoffa AL, et al. The role of immunohistochemical analysis in the evaluation of EML4-ALK gene rearrangement in lung cancer.Appl Immunohistochem Mol Morphol. 2015;23(4): 239-244.
16. Kotoula V, Bobos M, Vassilakopoulou M, et al. Intact or brokenapart RNA:an alternative concept for ALK fusion screening in non-small cell lung cancer (NSCLC). Appl Immunohistochem Mol Morphol. 2015;23(1): 60-70.
17. Cutz JC, Craddock KJ, Torlakovic E, et al. Canadian anaplastic lymphoma kinase study:a model for multicenter standardization and optimization of ALK testing in lung cancer. J Thorac Oncol. 2014;9(9): 1255-1263.
18. Blackhall FH, Peters S, Bubendorf L, et al. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. J Clin Oncol. 2014;32(25): 2780-2787.
19. Wang J, Cai Y, Dong Y, et al. Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR. PLoS ONE. 2014;9(7): e101551.
20. Tuononen K, Kero M, Mäki-Nevala S, et al. ALK fusion and its association with other driver gene mutations in Finnish nonsmall cell lung cancer patients. Genes Chromosomes Cancer. 2014;53(11): 895-901.
21. Alì G, Proietti A, Pelliccioni S, et al. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment. Arch Pathol Lab Med. 2014;138(11): 1449-1458.
22. Demidova I, Barinov A, Savelov N, et al. Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription- polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with nonsmall cell lung cancer: potential advantages and methodologic pitfalls. Arch Pathol Lab Med. 2014;138(6): 794-802.
23. Le Quesne J, Maurya M, Yancheva SG, et al. A comparison of immunohistochemical assays and FISH in detecting the ALK translocation in diagnostic histological and cytological lung tumor material. J Thorac Oncol. 2014;9(6): 769-774.
24. Wynes MW, Sholl LM, Dietel M, et al. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol. 2014; 9(5): 631-638.
25. Zhou J, Zhao J, Sun K, et al. Accurate and economical detection of ALK positive lung adenocarcinoma with semiquantitative immunohistochemical screening. PLoS ONE. 2014;9(3): e92828.
26. Zwaenepoel K, Van Dongen A, Lambin S, Weyn C, Pauwels P. Detection of ALK expression in non-small-cell lung cancer with ALK gene rearrangements—comparison of multiple immunohistochemical methods. Histopathology. 2014;65(4):539-548.
27. Hutarew G, Hauser-Kronberger C, Strasser F, Llenos IC, Dietze O. Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH. Histopathology. 2014;65(3): 398-407.
28. Cabillic F, Gros A, Dugay F, et al. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J Thorac Oncol. 2014;9(3):295-306.
29. Gruber K, Horn H, Kalla J, et al. Detection of rearrangements and transcriptional up-regulation of ALK in FFPE lung cancer specimens using a novel, sensitive, quantitative reverse transcription polymerase chain reaction assay. J Thorac Oncol. 2014; 9(3):307-315.
30. Shan L, Lian F, Guo L, Yang X, Ying J, Lin D. Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement. Diagn Pathol. 2014;9(1): 3.
31. Han XH, Zhang NN, Ma L, et al. Immunohistochemistry reliably detects ALK rearrangements in patients with advanced non-small-cell lung cancer. Virchows Arch. 2013;463(4): 583-591.
32. Wu YC, Chang IC, Wang CL, et al. Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS ONE. 2013;8(8): e70839.
33. Takamochi K, Takeuchi K, Hayashi T, Oh S, Suzuki K. A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer:a comprehensive study of surgically treated Japanese patients. PLoS ONE. 2013;8(8): e69794.
34. Li Y, Pan Y, Wang R, et al. ALK-rearranged lung cancer in Chinese:a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR. PLoS ONE. 2013;8(7): e69016.
35. Ying J, Guo L, Qiu T, et al. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann Oncol. 2013;24(10): 2589-2593.
36. Selinger CI, Rogers TM, Russell PA, et al. Testing for ALK rearrangement in lung adenocarcinoma:a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2013;26(12): 1545-1553.
37. Zhang YG, Jin ML, Li L, et al. Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffinembedded tissues. PLoS ONE. 2013;8(5): e64821.
38. Sholl LM, Weremowicz S, Gray SW, et al. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol. 2013;8(3): 322-328.
39. Martinez P, Hernández-Losa J, Montero MÁ, et al. Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. PLoS ONE. 2013;8(1): e52261.
40. Chen TD, Chang IC, Liu HP, et al. Correlation of anaplastic lymphoma kinase overexpression and the EML4-ALK fusion gene in non-small cell lung cancer by immunohistochemical study. Chang Gung Med J. 2012;35(4): 309-317.
41. Park HS, Lee JK, Kim DW, et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer. 2012;77(2): 288-292.
42. Popat S, Gonzalez D, Min T, et al. ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma. Lung Cancer. 2012;75(3): 300-305.
43. Kim H, Yoo SB, Choe JY, et al. Detection of ALK gene rearrangement in non-small cell lung cancer:a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol. 2011; 6(8): 1359-1366.
44. Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol. 2011; 6(3): 459-465.
45. Paik JH, Choe G, Kim H, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer:correlation with fluorescence in situ hybridization. J Thorac Oncol. 2011;6(3): 466-472.
46. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009;15(16): 5216-5223.
47. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc:a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006;6(1): 31.
48. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153): 561-566.
49. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14(13): 4275-4283.
50. Perner S, Wagner PL, Demichelis F, et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia. 2008;10(3): 298-302.
51. Martelli MP, Sozzi G, Hernandez L, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol. 2009;174(2): 661-670.
52. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26): 4247-4253.
53. Wong DW, Leung EL, So KK, et al; University of Hong Kong Lung Cancer Study Group. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115(8): 1723-1733.
54. Tuononen K, Sarhadi VK, Wirtanen A, et al. Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas detected by FISH, immunohistochemistry, and real-time RT-PCR:a comparison of four methods. Biomed Res Int. 2013;2013:757490.
55. Bahreini F, Soltanian AR, Mehdipour P. A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer. Breast Cancer. 2015;22(6): 615-625.
56. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009;15(9): 3143-3149.